Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2004

View Archived Issues

Glucose-lowering effects of liraglutide in patients with type 2 diabetes

Update on the clinical benefits of rasagiline in PD

New data confirm Lovenox is effective antithrombotic for ACS

Ampligen study in HIV/hepatitis C coinfected patients to begin

Hemantane has protective effect in MPP+ model of Parkinson's

European marketing authorization for Vesicare for overactive bladder

Allergan files INDs for PEP-005 Topical

European approval for Pariet for Zollinger-Ellison syndrome

Phase I study for neuroprotectant KTX-0101

Isotechnika cleared to commence U.S. phase Ib study of TAFA-93

European orphan medicinal product status for Mepat in osteosarcoma

New phase III study for RSD-1235

Enrollment open at European sites in CoFactor phase II study

Celmed BioSciences completes acquisition of NewBiotics

Lorus expands Canadian prostate cancer study of GTI-2501 and docetaxel

Xoma reviews recent pipeline progress

Phosphodiesterase 4 inhibitors claimed by Memory Pharmaceuticals

Factor Xa and VIIa inhibitors reported by Merck KGaA

Vanilloid receptor antagonists for the treatment of pain

AstraZeneca describes glucokinase activators

Silicon compounds for GnRH related disorders

Bayer describes agents for hyperproliferative disorders

Lyrica approved in E.U.

A clinical trial evaluates the efficacy of montelukast in migraine prophylaxis

Antagonists of antiapoptotic protein for the treatment of cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...